When was Vyvgart approved by the FDA?

Written by Lindsey Shapiro, PhD | April 6, 2023

When was Vyvgart approved by the FDA?

Category: Vyvgart

The U.S. Food and Drug Administration (FDA) approved Vyvgart in December 2021 to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. The decision marked the first approval of an FcRn blocker in the U.S. and also made Vyvgart the first approved therapy designed to reduce disease-causing antibodies.

Print This Article

About the Author

Lindsey Shapiro, PhD Lindsey is a senior science writer for Bionews with a PhD in neuroscience from Emory University. There, she was awarded a predoctoral fellowship from the American Epilepsy Society to study the role of new therapeutic approaches for treatment of resistant forms of epilepsy. She also spent time as a postdoctoral researcher exploring the role of inflammation in epilepsy. With a passion for ensuring that science is accessible to all, Lindsey joined Bionews as a science writer in 2022.